Literature DB >> 12773514

Up-regulated expression of MICA on activated T lymphocytes involves Lck and Fyn kinases and signaling through MEK1/ERK, p38 MAP kinase, and calcineurin.

Luciana L Molinero1, Mercedes B Fuertes, Leonardo Fainboim, Gabriel A Rabinovich, Norberto W Zwirner.   

Abstract

Major histocompatibility complex class I-related chain (MICA) is a cell stress-regulated molecule recognized by cytotoxic cells expressing the NKG2D molecule. MICA can be induced on T cells after CD3 or CD28 engagement. Here, we investigated the intracellular pathways leading to activation-induced expression of MICA. The Src kinase inhibitor PP1 inhibited up-regulated expression of MICA on anti-CD3-stimulated T cells. Downstream signaling routes involved mitogen-activated protein kinase (MAPK) kinase (MEK)1/extracellular signal-regulated kinase (ERK), p38 MAPK, and calcineurin, as MICA expression was prevented by U0126, SB202190, cyclosporin A, and FK506. Also, Lck and Fyn as well as MEK1/ERK and p38 MAPK were found to regulate MICA expression in anti-CD28/phorbol 12-myristate 13-acetate-stimulated T cells. Expression of MICA on activated T cells involved interleukin-2-dependent signaling routes triggered by Janus tyrosine kinases/signal transducer and activators of transcription and p70(S)(6) kinase, as it could be inhibited by AG490 and rapamycin. This is the first demonstration of the intracellular pathways involved in activation-induced expression of MICA, which may reveal potential targets for immune intervention to modulate MICA expression in pathological disorders.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12773514     DOI: 10.1189/jlb.0602329

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  7 in total

1.  p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells.

Authors:  Alessandra Soriani; Cristiana Borrelli; Biancamaria Ricci; Rosa Molfetta; Alessandra Zingoni; Cinzia Fionda; Silvia Carnevale; Maria Pia Abruzzese; Maria Teresa Petrucci; Maria Rosaria Ricciardi; Giuseppe La Regina; Erica Di Cesare; Patrizia Lavia; Romano Silvestri; Rossella Paolini; Marco Cippitelli; Angela Santoni
Journal:  Oncoimmunology       Date:  2016-12-02       Impact factor: 8.110

2.  Manipulating the NKG2D Receptor-Ligand Axis Using CRISPR: Novel Technologies for Improved Host Immunity.

Authors:  Eric Alves; Emily McLeish; Pilar Blancafort; Jerome D Coudert; Silvana Gaudieri
Journal:  Front Immunol       Date:  2021-08-12       Impact factor: 7.561

3.  Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer.

Authors:  Jennifer D Wu; Lily M Higgins; Alexander Steinle; David Cosman; Kathy Haugk; Stephen R Plymate
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

4.  Loss of expression of MHC class I-related chain A (MICA) is a frequent event and predicts poor survival in patients with hepatocellular carcinoma.

Authors:  Jie Zhang; Zhuding Xu; Xingchun Zhou; Haibin Zhang; Ning Yang; Yousheng Wu; Yibing Chen; Guangshun Yang; Tingting Ren
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

5.  N-glycosylation of asparagine 8 regulates surface expression of major histocompatibility complex class I chain-related protein A (MICA) alleles dependent on threonine 24.

Authors:  Maiken Mellergaard; Sarah Line Skovbakke; Christine L Schneider; Felicia Lauridsen; Lars Andresen; Helle Jensen; Søren Skov
Journal:  J Biol Chem       Date:  2014-05-28       Impact factor: 5.157

6.  Broad MICA/B expression in the small bowel mucosa: a link between cellular stress and celiac disease.

Authors:  Yessica L Allegretti; Constanza Bondar; Luciana Guzman; Eduardo Cueto Rua; Nestor Chopita; Mercedes Fuertes; Norberto W Zwirner; Fernando G Chirdo
Journal:  PLoS One       Date:  2013-09-13       Impact factor: 3.240

7.  Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function.

Authors:  Claudia Manzini; Roberta Venè; Irene Cossu; Marina Gualco; Simonetta Zupo; Mariella Dono; Francesco Spagnolo; Paola Queirolo; Lorenzo Moretta; Maria Cristina Mingari; Gabriella Pietra
Journal:  Oncotarget       Date:  2016-09-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.